Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-beta-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.Liu, B., Trout, R.E.L., Chu, G.H., McGarry, D., Jackson, R.W., Hamrick, J.C., Daigle, D.M., Cusick, S.M., Pozzi, C., De Luca, F., Benvenuti, M., Mangani, S., Docquier, J.D., Weiss, W.J., Pevear, D.C., Xerri, L., Burns, C.J.
(2019) J. Med. Chem. --: --
- PubMed: 31765155
- DOI: 10.1021/acs.jmedchem.9b01518
- Primary Citation of Related Structures:
- PubMed Abstract:
- VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-beta-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa.
Hamrick, J.C.,Docquier, J.D.,Uehara, T.,Myers, C.L.,Six, D.A.,Chatwin, C.L.,John, K.J.,Vernacchio, S.F.,Cusick, S.M.,Trout, R.E.L.,Pozzi, C.,De Luca, F.,Benvenuti, M.,Mangani, S.,Liu, B.,Jackson, R.W.,Moeck, G.,Xerri, L.,Burns, C.J.,Pevear, D.C.,Daigle, D.M.
(2019) Antimicrob. Agents Chemother. --: --
A major resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β-lactamases can now confer resistance to other β-lactam drugs, including both ...
A major resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β-lactamases can now confer resistance to other β-lactam drugs, including both cephalosporins and carbapenems. The emergence and global spread of β-lactamase-producing multi-drug-resistant "superbugs" has caused increased alarm within the medical community due to the high mortality rate associated with these difficult-to-treat bacterial infections. To address this unmet medical need, we initiated an iterative program combining medicinal chemistry, structural biology, biochemical testing, and microbiological profiling to identify broad-spectrum inhibitors of both serine- and metallo-β-lactamase enzymes. Lead optimization, beginning with narrower-spectrum, weakly active compounds, provided 20 (VNRX-5133, taniborbactam), a boronic-acid-containing pan-spectrum β-lactamase inhibitor. In vitro and in vivo studies demonstrated that 20 restored the activity of β-lactam antibiotics against carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae. Taniborbactam is the first pan-spectrum β-lactamase inhibitor to enter clinical development.
Department of Biotechnology, Chemistry and Pharmacy , University of Siena , I-53100 Siena , Italy.,Venatorx Pharmaceuticals, Inc. , 30 Spring Mill Drive , Malvern , Pennsylvania 19355 , United States.,Department of Medical Biotechnology , University of Siena , I-53100 Siena , Italy.,UNT System College of Pharmacy , University of North Texas Health Science Center , 3500 Camp Bowie Boulevard , Fort Worth , Texas 76107-2699 , United States.